- UID
- 47274
- 在线时间
- 小时
- 注册时间
- 2004-8-16
- 最后登录
- 1970-1-1
- 主题
- 帖子
- 性别
- 保密
|
Hi everyone,
I would like to have a survey to seek any potential needs of current Harvard Business School Publishing reading material. My friend is a MBA degree post-graduate from a famous North America Business School. During his study, he applied registered as regular user of www.hbsp.com. Therefore, he could regularly visit the website and purchase the business school articles as professional reading material. The cost of each article is round USD $5-$8. Although it seems to be as simple as you are purchasing an iphone application in apple online store, actually the registration is much difficult and cost demanding. Now he has accumulated a lot of reading materials including many classic business cases.
We are wondering if there are any potential needs of these professional reading materials. However, since we would have cost to collect the reading material and other maintenance cost since, we may not be able to share them in free.
Anyone interested in or any concern pls let me know! We will figure out a proper way to share.
Hereby below is short list of reading materials focus on Pharmaceutical & Healthcare:
01 Note on Biotech Business Development/Case 02 Novartis AG: Science-Based Business/Case 03 Pfizer Inc.: Building an Innovation Center/Case 04 Pfizer Inc.: Global Protection of Intellectual Property/Case 05 Strategy in the 21st Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc./Case 06 Recent Developments in the Ranbaxy Case/Case 07 Global Talent Management at Novartis/Case 08 Immusol and Novartis/Case 09 Transforming Human Resource at Novartis: The Human Resource Information System (HRIS)/Case 10 eBusiness@Novartis/Case 11 Norvatis: The Challenge of Success (A) (B)/Case 12 Norvatis: The Challenge of Success (C) (D)/Supplement 13 Novartis: Betting on Life Sciences/Case 14 Hans Fritz at Novartis Thailand (A): The First Month/Case 15 Hans Fritz at Novartis Thailand (B): The First Six Months/Supplement 16 Hans Fritz at Novartis Thailand (C)/Supplement 17 Hans Fritz at Novartis Thailand (D): The First 18 Months/Supplement 18 Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry/Case 19 Jan Eriksson at Novartis Indonesia (A)/Case 20 Jan Eriksson at Novartis Indonesia (B)/Supplement 21 How to Change the World (HBR Case Study & Commentary/Case 22 When Supply Is of Public Interest: Roche & Tamiflu/Case 23 Roche & Tamiflu: Doing Business in the Shadow of Pandemic/Case 24 Overpromoted and Over His Head (HBR Case Study and Commentary)/Case 25 Before the Fall: Lehman Brothers 2008/Case 26 Nomura’s Global Growth: Picking up Pieces of Lehman/Case 27 Investment Banking in 2008 (A): Rise and Fall of the Bear/Case 28 Investment Banking in 2008 (B): A Brave New World/Supplement 29 Merck & Co.: Evaluating a Drug Licensing Opportunity/Case 30 Driving Transformational Change: Strategy Execution at Merck/Balanced Score Card 31 Merck: Managing Vioxx (A)/Case 32 Merck: Managing Vioxx (B) (C) (D) (E) (F) (G)/Supplement 33 Merck: Global Heath and Access to Medicines/Case 34 Merck: Pricing Gardasil/Case 35 Merck: Conflict and Change/Case 36 Merck Latin America (A)/Case 37 Merck Latin America (B): Argentina/Supplement 38 Merck Latin America (C): Brazil/Case 39 Merck Latin America (D): Mexico/Case 40 Discovering the Future: R&D Strategy at Merck/Case 41 Merck Global Health Initiatives (A)/Case 42 Merck Global Health Initiatives (B): Botswana/Case 43 Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)/Case 44 Merck & Co., Inc.: Corporate Strategy, Organization and Culture (B)/Supplement 45 Merck & Co., Inc. (A) (B)/Case 46 Merck & Co., Inc. (C)/Supplement 47 Merck-Banyu/Case 48 Bayer AG (A) (B)/Case 49 Bayer & Millennium Pharmaceuticals: Success Based on Perfect Interaction/Case 50 Why Are We Losing All Our Good People? (HBR Case Study and Commentary)/Case
Best Regards! |
|